ArticleJACS Au2026
Spectroscopically Deciphering the Formation and Reactivity of a High-Valent Ni(IV)Cl
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-Valent Late Transition Metal-Oxo Complexes: Breaking Boundaries at the Oxo Wall and Beyond.Chemical reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent investigations have demonstrated the appeal of using Ni-(II) complexes with redox-active ligands in fields like catalysis, electrochemistry, or materials sciences. Ni-(salen) complexes have particularly been shown to exhibit temperature-dependent equilibrium based on the localization of the unpaired spin. However, the usage of salen as a ligand has always restricted the characterization of a Ni-(IV) species with Ni bearing both the oxidizing equivalents. Hence, the current work aims to develop the biologically relevant pseudopeptide-based Ni complex that enables the formation and trapping of a high-valent Ni-(IV) species from its Ni-(II) precursor. The synthesized [LNi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.